Two oral drugs for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two oral medications for people with advanced colorectal cancer who cannot tolerate stronger chemotherapy. The goal is to see if this gentler approach slows tumor growth and improves quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have advanced colorectal cancer that has spread and is confirmed by biopsy.
- You have not yet had any treatment for the metastatic disease.
- You are not able to receive standard intensive chemo (oxaliplatin or irinotecan) due to side effects or health issues.
- You have at least one tumor that can be measured on scans.
- Your overall health and organ function (blood counts, liver, kidneys, and clotting) are within normal limits.
- You are not pregnant and will use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
Hear when a new CRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.